Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Complementary and alternative medicines (CAM)

Home > PJ (current issue) > Letters | Search

PJ Online homeThe Pharmaceutical Journal
Vol 276 No 7382 p12
7 January 2006

This article
Reprint   Photocopy

PDF 80K, Acrobat Reader

Letters

· Influenza pandemic
· Preregistration training
· COX-2s
· CAM
· Controlled drugs
· Medicines use reviews
· Pharmacy practice


Letters to the Editor

Complementary and alternative medicines (CAM)

A pragmatic answer to consumer protection can be found

From Dr R. J. Woodward, MRPharmS

Recent years have seen an upsurge in demand for complementary and alternative medicines. Concomitantly, CAM research in academic institutions has increased. Yet results have been disappointing, inconclusive and have done CAM no favours.

The high-profile academic department in Exeter and its publications run by Edzard Ernst have demonstrated that resources for research are meagre because the CAM industry and profession are no match for big pharmaceutical companies and modern medicine. The truth is they never will be and I am puzzled why anyone wastes resources in the hopeless cause of trying to let CAM endeavour to emulate its giant competitor. Strict judgement of CAM by the criteria designed for modern drugs and medical interventions can never succeed.

Professor Ernst and his cohorts are clear in their demands that CAM treatments must be evidence-based with clinical trials that are independently replicated and validated. Practitioners of CAM who do not rely on such evidence are described as dishonest. That is disgraceful but should signal to the CAM movement that he is no friend. Much modern medicine does not meet these standards but does he describe doctors as dishonest? Misguided is a better word when all one is expressing is an opinion. Professor Ernst describes himself as a wishful thinking idealist — I would call him a blinkered academic with no grasp of reality.

Not long ago the organisation Healthwatch used the word “fraud” in one of its publications in connection with CAM and, rightly, heavy libel damages had to be paid. My experience of CAM practitioners is that most are decent, dedicated people who are passionate about what they are doing. Above all, their patients are usually satisfied.

Many advocates of CAM believe they can protect themselves by taking the regulatory route. Some demand a regulatory body for every area of CAM — resources for both regulators and researchers coming from where?

The philosophy behind CAM health care is different from modern medicine. The clinical treatment methods are too diverse even within each CAM group to make meaningful research results attainable with infinite financial and human resources. Since no patents are available for CAM treatments, the accumulation of significant research funds is impossible. The reference to the CHARM trial (PJ, 10 December, p714) showing adherence to medication, even placebo, improves outcomes is surely most relevant in the CAM context.

I believe a pragmatic answer to consumer protection could be found without hyper-regulation if all sides admitted that the resource problem was insoluble. If it is not then waste will continue to no avail except the benefit of Professor Ernst, bureaucrats and the army of CAM technical and legal advisers and consultants.

Robert Woodward
Liss, Hampshire

 

EDZARD ERNST replies:

Robert Woodward argues in favour of double standards: “judgement of CAM by the criteria designed for modern drugs and medical interventions can never succeed” because “the philosophy behind CAM … is different”. This seems a big step, albeit in the wrong direction. If we do not assess health care on the basis of reliable evidence, by what should we evaluate it? The answer probably is by belief.

Thus CAM becomes a belief system and not health care. In this case, we should place it in churches rather than hospitals. I am convinced that double standards, even though they may preserve the interests of certain CAM groups, are to the detriment of patients and the public.

Luckily this view is fast becoming accepted wisdom. The House of Lords Science and Technology Sixth Report (2000) states: “CAM practitioners and researchers should attempt to build up an evidence base with the same rigour as is required of conventional medicine.”

Send your letter to The Editor

Previous Topic (COX-2s)
Next Topic (Controlled drugs)

Back to Top

©The Pharmaceutical Journal

Citation: The Pharmaceutical Journal URI: 20016347

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Introduction to Clinical Pharmaceutics (An)

    Introduction to Clinical Pharmaceutics (An)

    This unique textbook covers the role of basic pharmaceutics in clinical outcomes and in explaining the behaviour of medicines in the body.

    £27.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.